Pfizer lines up as much as $1.5 billion from Blackstone to back its obesity program

Pfizer said it has secured access to up to $1.5 billion from Blackstone to help fund development of its obesity program, according to a report published Nov. 12 by Yahoo Finance.

The arrangement is designed to provide capital for the ongoing development of berobenatide, Pfizer’s obesity drug candidate, and is structured to cover work through 2028, the report said.

While the financing would flow from Blackstone, Pfizer emphasized in the reporting that it retains full control of the obesity program. The report characterizes the transaction as funding support rather than a handoff of decision-making.

Details of the deal terms beyond the headline size and the timeline were not included in the material provided for this brief. The report did not, for example, disclose how the funding is triggered, whether it is released in tranches tied to milestones, or what any repayment or economics look like.

For Pfizer, the attraction of this type of financing is straightforward, even if the specific mechanics are not described in the available text: obesity drug development can be capital-intensive, and long development timelines can strain internal budgets. Bringing in an external capital partner can help smooth cash needs without changing who is driving the program.

For Blackstone, the reported structure reflects the growing role of private capital in late-stage biotech and healthcare R&D. Investors have increasingly sought exposure to drug development outcomes while relying on operating-company control to manage execution.